WaveMan
WaveMan · Company
ASND · Ascendis Pharma A/S
> Search tickers & screens ⌘K
LIVE
← All companies

ASND Ascendis Pharma A/S (ASND) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001612042
Quote by TradingView
C-suite buying · 1Form 144 · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
191
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $330.0K priced

What the filings say about ASND

Insiders, 180 days
-$4.7M net sold
2 buyers · 3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$872.9K
2 notices

Ascendis Pharma A/S insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Ascendis Pharma A/S insiders sold a net $4.7M of stock across 12 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Bodenhoff Mads
SVP & PAO
SELL
2026-09-09 SECtraded 2026-09-08
3,000
$810.6K
-6.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 1 other insider sold within 30 days.
  • 191 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & PAO Bodenhoff Mads sold about $810.6K of ASND on Sep 8, 2026; 1 other insider sold within 30 days and 191 funds added in the latest 13F quarter.
HOLTUG LARS
Director
SELL
2026-09-03 SECtraded 2026-09-02
236
$62.3K
-9.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 5.9% of the 4,000 shares held after it.
  • 1 other insider sold within 30 days.
  • 191 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HOLTUG LARS sold about $62.3K of ASND on Sep 2, 2026; 1 other insider sold within 30 days and 191 funds added in the latest 13F quarter.
BIENAIME JEAN JACQUES
Director
BUY
2026-08-18 SECtraded 2026-08-14
1,100
$270.4K
-5.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 29, 2026.
  • +8.2% median (+8.2% mean) 90-day return after 2 previous buys.
  • The trade is 55.0% of the 2,000 shares held after it.
  • No other insider bought within 30 days.
  • 191 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BIENAIME JEAN JACQUES bought about $270.4K of ASND on Aug 14, 2026, the largest insider purchase at the company on our record; 191 funds added in the latest 13F quarter.
BIENAIME JEAN JACQUES
Director
BUY
2026-08-18 SECtraded 2026-08-14
900
$222.2K
-5.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 29, 2026.
  • +8.2% median (+8.2% mean) 90-day return after 2 previous buys.
  • The trade is 31.0% of the 2,900 shares held after it.
  • No other insider bought within 30 days.
  • 191 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BIENAIME JEAN JACQUES bought about $222.2K of ASND on Aug 14, 2026, the largest insider purchase at the company on our record; 191 funds added in the latest 13F quarter.
SMITH SCOTT THOMAS
EVP & Chief Financial Officer
BUY
2026-06-02 SEC
100
$21.9K
+13.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 29, 2026.
  • The trade is 2.3% of the 4,367 shares held after it.
  • 1 other insider bought within 30 days.
  • 191 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Financial Officer SMITH SCOTT THOMAS bought about $21.9K of ASND on Jun 2, 2026; 1 other insider bought within 30 days and 191 funds added in the latest 13F quarter.
12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 7 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.7M over 180 days
-$380.3K over 90 days
below 79% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
191 funds bought in last quarter
more than 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.3% of the float short (float per yahoo 2026-10-26) · 3.7 days to cover · settled 2026-09-30
more than 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ASND

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+20.9%12M
-3%+10%+23%+37%2025-102025-122026-022026-042026-062026-082026-10 2026-05-11 · JENSEN FLEMMING STEEN sold $4.6M2026-09-08 · Bodenhoff Mads sold $810.6K2026-08-14 · BIENAIME JEAN JACQUES bought $270.4K2026-08-14 · BIENAIME JEAN JACQUES bought $222.2K2026-09-02 · HOLTUG LARS sold $62.3K2026-05-29 · SMITH SCOTT THOMAS bought $55.8K2026-05-26 · BIENAIME JEAN JACQUES bought $47.9K2026-05-26 · BIENAIME JEAN JACQUES bought $47.2K2026-05-29 · BIENAIME JEAN JACQUES bought $44.8K2026-05-29 · BIENAIME JEAN JACQUES bought $44.5K2026-05-29 · BIENAIME JEAN JACQUES bought $22.4K2026-06-02 · SMITH SCOTT THOMAS bought $21.9K2026-09-08 · Bodenhoff Mads filed to sell $810.6K2026-09-02 · HOLTUG LARS filed to sell $62.3K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ASND: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
10,281,496 sh
$2.7B
Avoro Capital Advisors LLC
5,111,111 sh
$1.4B
WESTFIELD CAPITAL MANAGEMENT CO LP
4,798,267 sh
$1.3B
Jupiter Topco LLC
3,648,772 sh
$973.4M
FMR LLC
3,545,575 sh
$945.7M

Congress trades in ASND

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ASND planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Bodenhoff Mads
Filed 2026-09-08
$810.6K
HOLTUG LARS
Filed 2026-09-02
$62.3K

ASND mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Touchstone Strategic Trust-Touchstone Mid Cap Growth Fund
$83.7M position · as of 2026-06-30
3.7%
AlphaCentric Life Sciences and Healthcare Fund
$1.2M position · as of 2026-06-30
2.6%
Focused Dynamic Growth Fund
$52.2M position · as of 2026-07-31
2.6%
American Century Focused Dynamic Growth ETF
$10.4M position · as of 2026-05-31
2.5%
Miller Market Neutral Income Fund
$6.2M position · as of 2026-07-31
1.7%
Victory RS Select Growth Fund
$1.5M position · as of 2026-06-30
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
13 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
7
Phase 2
2 active
3
Phase 3
2 active
3
Not applicable
2 active
What changed recently
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 1
2026-10-14 · Completion moved 2027-08 → 2027-09
Phase 2
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 1
2026-10-14 · Recruiting → Active Not Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.7M sold by insiders over 180 days, 191 funds added last quarter, $872.9K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ASND financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
no equity line filed
Return on assets
-18.4%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Gross profit$625.2M$319.4M$222.3M$39.0M
Net income-$228.0M-$378.1M-$481.4M-$583.2M
SEC XBRL, fiscal years, as known on 2026-10-27

ASND Stock Sonar score 3/7 axes

Find similar shapesCompare

ASND ranks highest on institutional and government (89th percentile) and risk and compliance (57th), and lowest on insider conviction (50th), among Pharma & Biotech peers.

Insider conviction
50
Inputs
  • Net Form 4 buying (codes P and S), 180d-$4.7M · 19 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Institutional and government
89
Inputs
  • Funds adding, latest quarter191 · 89 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
57
Inputs
  • Short interest, % of float+5.3% · 57 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
  • Profitability needs 2 of 4 inputs, 1 present: fewer than four consecutive quarters of operating income; no equity line filed
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ASND filings, in plain words

Are Ascendis Pharma A/S insiders buying or selling ASND?

In the 180 days to 2026-10-27, Ascendis Pharma A/S insiders were net sellers, a net $4.7M: $777.1K of purchases and $5.5M of sales reported on Form 4, by 2 buyers and 3 sellers.

Are there planned insider sales of ASND?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $872.9K of stock; the latest, by Bodenhoff Mads, was filed 2026-09-08.

Read the full summary

In the 180 days to 2026-10-27, Ascendis Pharma A/S insiders were net sellers of ASND, a net $4.7M across purchases and sales reported on Form 4 by 2 buyers and 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $872.9K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies